CN103313988B - 咪唑并三嗪酮化合物 - Google Patents

咪唑并三嗪酮化合物 Download PDF

Info

Publication number
CN103313988B
CN103313988B CN201180055157.9A CN201180055157A CN103313988B CN 103313988 B CN103313988 B CN 103313988B CN 201180055157 A CN201180055157 A CN 201180055157A CN 103313988 B CN103313988 B CN 103313988B
Authority
CN
China
Prior art keywords
imidazo
trans
alkyl
triazine
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180055157.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103313988A (zh
Inventor
A·里普卡
G·夏皮罗
A·麦克里内尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ian Wood Pharmaceuticals
Original Assignee
EnVivo Phamaceuticals Inc
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EnVivo Phamaceuticals Inc, Ironwood Pharmaceuticals Inc filed Critical EnVivo Phamaceuticals Inc
Publication of CN103313988A publication Critical patent/CN103313988A/zh
Application granted granted Critical
Publication of CN103313988B publication Critical patent/CN103313988B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201180055157.9A 2010-09-20 2011-09-20 咪唑并三嗪酮化合物 Expired - Fee Related CN103313988B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38469410P 2010-09-20 2010-09-20
US61/384,694 2010-09-20
PCT/US2011/052399 WO2012040230A1 (en) 2010-09-20 2011-09-20 Imidazotriazinone compounds

Publications (2)

Publication Number Publication Date
CN103313988A CN103313988A (zh) 2013-09-18
CN103313988B true CN103313988B (zh) 2016-06-08

Family

ID=44720178

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180055157.9A Expired - Fee Related CN103313988B (zh) 2010-09-20 2011-09-20 咪唑并三嗪酮化合物

Country Status (16)

Country Link
US (3) US20120157458A1 (https=)
EP (2) EP2619208B1 (https=)
JP (2) JP5855109B2 (https=)
CN (1) CN103313988B (https=)
AR (1) AR083058A1 (https=)
AU (2) AU2011305568B2 (https=)
BR (1) BR112013008140A8 (https=)
CA (1) CA2811714C (https=)
DK (1) DK2619208T3 (https=)
ES (1) ES2610360T3 (https=)
MX (1) MX2013003093A (https=)
PL (1) PL2619208T3 (https=)
RU (1) RU2603140C2 (https=)
TW (1) TWI541244B (https=)
UY (1) UY33616A (https=)
WO (1) WO2012040230A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513524B2 (en) 2015-07-07 2019-12-24 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US12006319B2 (en) 2018-05-25 2024-06-11 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US12213975B2 (en) 2018-08-31 2025-02-04 Cardurion Pharmaceuticals, Inc. PDE9 inhibitors for treating sickle cell disease

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2619208B1 (en) 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
BR112015007731B1 (pt) * 2011-10-10 2022-05-31 H. Lundbeck A/S Composto, composição farmacêutica que o compreende e uso do mesmo
BR112014018199A8 (pt) * 2012-01-26 2021-03-02 H Lundbeck As inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
JP2016503395A (ja) 2012-10-31 2016-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 病害生物防除剤としての複素環化合物
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
TW201639851A (zh) * 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 雙環咪唑衍生物
TW201643167A (zh) * 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
MX2018016127A (es) 2016-07-06 2019-05-30 Imara Inc Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
WO2018073251A1 (en) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
AU2017350473A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
WO2018078042A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
CN115746003B (zh) * 2017-05-26 2024-08-09 卡都瑞恩医药公司 制备和使用pde9抑制剂的方法
WO2020102374A1 (en) * 2018-11-14 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Targeting of makap-pde4d3 complexes in neurodegenerative disease
KR102712818B1 (ko) * 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
CA3155013A1 (en) * 2019-10-21 2021-04-29 Ki Ho Lee Use of imidazopyrimidine or imidazotriazine compound for prevention, alleviation, or treatment of developmental disability
CN112724079A (zh) * 2021-02-04 2021-04-30 康化（上海）新药研发有限公司 一种6-甲氧基吡啶甲酸甲酯的合成方法
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096811A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Pde9 inhibitors for treating type 2 diabetes, metabokic syndrome, and cardiovascular disease
CN1575191A (zh) * 2001-11-02 2005-02-02 辉瑞产品公司 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病
CN101687876A (zh) * 2007-05-11 2010-03-31 辉瑞有限公司 氨基杂环化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE19750085A1 (de) * 1997-11-12 1999-05-20 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone
CA2395558C (en) 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2006127368A2 (en) 2005-05-20 2006-11-30 Lexicon Genetics Incorporated Methods for synthesizing imidazotriazinones
JP2008543968A (ja) 2005-06-28 2008-12-04 オーキッド リサーチ ラボラトリーズ リミテッド 新規なピラゾロピリミジノン誘導体
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
EP2619208B1 (en) 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
BR112014018199A8 (pt) 2012-01-26 2021-03-02 H Lundbeck As inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1575191A (zh) * 2001-11-02 2005-02-02 辉瑞产品公司 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病
WO2004096811A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Pde9 inhibitors for treating type 2 diabetes, metabokic syndrome, and cardiovascular disease
CN101687876A (zh) * 2007-05-11 2010-03-31 辉瑞有限公司 氨基杂环化合物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513524B2 (en) 2015-07-07 2019-12-24 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US11608342B2 (en) 2015-07-07 2023-03-21 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US12006319B2 (en) 2018-05-25 2024-06-11 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US12466832B2 (en) 2018-05-25 2025-11-11 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US12213975B2 (en) 2018-08-31 2025-02-04 Cardurion Pharmaceuticals, Inc. PDE9 inhibitors for treating sickle cell disease

Also Published As

Publication number Publication date
ES2610360T3 (es) 2017-04-27
US9540380B2 (en) 2017-01-10
DK2619208T3 (en) 2017-01-30
JP2016104747A (ja) 2016-06-09
BR112013008140A2 (pt) 2017-12-05
US20170152265A1 (en) 2017-06-01
BR112013008140A8 (pt) 2018-04-03
RU2013118362A (ru) 2014-10-27
PL2619208T3 (pl) 2017-03-31
EP3181566A1 (en) 2017-06-21
AU2016200970A1 (en) 2016-03-03
AR083058A1 (es) 2013-01-30
EP2619208A1 (en) 2013-07-31
CA2811714A1 (en) 2012-03-29
CN103313988A (zh) 2013-09-18
US20120157458A1 (en) 2012-06-21
EP2619208B1 (en) 2016-11-09
WO2012040230A1 (en) 2012-03-29
US20140330014A1 (en) 2014-11-06
MX2013003093A (es) 2013-10-28
CA2811714C (en) 2017-11-21
AU2011305568B2 (en) 2015-12-10
AU2011305568A1 (en) 2013-04-04
UY33616A (es) 2012-04-30
TWI541244B (zh) 2016-07-11
RU2603140C2 (ru) 2016-11-20
HK1187908A1 (en) 2014-04-17
JP2013540755A (ja) 2013-11-07
TW201217381A (en) 2012-05-01
JP5855109B2 (ja) 2016-02-09

Similar Documents

Publication Publication Date Title
CN103313988B (zh) 咪唑并三嗪酮化合物
US9969742B2 (en) Imidazotriazinone compounds
CN101305011B (zh) 吡啶衍生物及其在治疗精神障碍中的用途
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
CN106458912A (zh) 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途
EA025186B1 (ru) НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
CN115335376A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶（btk）及其使用方法
RS65308B1 (sr) Biciklična ketonska jedinjenja i postupci za njihovu upotrebu
TW201609708A (zh) 新穎２，５－經取代之嘧啶
CN112771032A (zh) 作为第四代egfr抑制剂的嘧啶吡唑类化合物
HK40076737A (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
HK1187908B (en) Imidazotriazinone compounds
HK1234039A1 (en) Imidazotriazinone compounds
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK1142595B (en) Amino-heterocyclic compounds
HK1219276B (zh) 二杂芳基化合物及其用途
HK1142595A1 (en) Amino-heterocyclic compounds
HK1213560B (en) C-linked heterocycloalkyl substituted pyrimidines and their uses
HK1234395B (zh) 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途
HK1213560A1 (zh) C-连接的杂环烷基取代的嘧啶类和它们的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Forum Pharmaceuticals Co., Ltd.

Address before: Massachusetts, USA

Applicant before: En Vivo Pharmaceuticals Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: EN VIVO PHARMACEUTICALS INC. TO: FORUM PHARMACEUTICAL CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160928

Address after: Massachusetts, USA

Patentee after: Ian Wood pharmaceuticals

Address before: Massachusetts, USA

Patentee before: Forum Pharmaceuticals Co., Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160608

Termination date: 20180920